Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Rhea-AI Summary
Cryoport (Nasdaq: CYRX) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026 after U.S. markets close.
Management will issue a review document at 4:05 p.m. ET and host a questions-and-answers conference call at 5:00 p.m. ET with an accompanying slide deck; replay available through March 10, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – CYRX
On the day this news was published, CYRX gained 1.44%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CYRX is up 1.33% while key logistics peers RLGT, FWRD, FLX and PAL show declines and PBI is flat, indicating a stock-specific move rather than a sector-wide shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Product launch | Positive | -2.3% | Launch of MVE Fusion 800 self-sustaining cryogenic freezer for space-limited labs. |
| Nov 04 | Earnings results | Positive | +2.0% | Q3 2025 revenue growth, higher margins, and raised full-year revenue guidance. |
| Oct 30 | Certification news | Positive | -2.6% | ISO 21973:2020 certification for human cell transport and related accolades. |
Recent operational and certification news tended to coincide with modest declines, while the last earnings release saw a positive price reaction.
Over the past several months, Cryoport has combined operational milestones with financial progress. An October 2025 update highlighted ISO 21973:2020 certification for transport of human cells, but shares fell afterward. In November 2025, Q3 results showed revenue growth and improved margins, with the stock rising about 2%. A February 2026 product launch for the MVE Fusion 800 cryogenic freezer was followed by a small decline. Today’s scheduling of the Q4 and full-year 2025 results fits into this pattern of steady operational and financial communication.
Market Pulse Summary
This announcement sets the timetable for Cryoport’s fourth quarter and full-year 2025 financial results and outlines a Q&A-focused conference call with a supporting review document. It follows recent product and certification milestones and prior revenue growth reported for Q3 2025. Investors may focus on how the upcoming release updates revenue trends, margins, and balance sheet strength, while also watching for commentary on strategic initiatives and any changes in business outlook.
AI-generated analysis. Not financial advice.
In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Tuesday, March 3, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at 5:00 p.m. ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information
Date: | Tuesday, March 3, 2026 |
Time: | 5:00 p.m. ET |
Dial-in numbers: | 1-800-717-1738 ( |
Confirmation code: | Request the "Cryoport Call" or Conference ID: 1189463 |
Live webcast:
| 'Investor Relations' section at www.cryoportinc.com or click here.
|
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until March 10, 2026. To access the replay, dial 1-844-512-2921 (
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Headquartered in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-3-2026-302689122.html
SOURCE Cryoport, Inc.
FAQ
When will Cryoport (CYRX) release Q4 and full year 2025 results?
What time is the Cryoport (CYRX) earnings conference call on March 3, 2026?
How can investors join the Cryoport (CYRX) March 3, 2026 earnings call?
Where will Cryoport (CYRX) post the March 3, 2026 review document and replay?
How long will the Cryoport (CYRX) earnings call replay be available by phone?
